Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | PLAU | P00749 | 1/20 | 0.57 |
| ▸ | NCF1 | P14598 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22926877 | 0.79 | LMNA (0.47) | KDM4ELMNAPOLBCASP6PLAU | |
| SCHEMBL31143623 | 0.78 | CYP1A2 (0.59) | KDM4EPOLBNCF1MEN1KMT2A | |
| SCHEMBL8275784 | 0.78 | CYP1A2 (0.59) | KDM4EPOLBNCF1MEN1KMT2A | |
| SCHEMBL1500224 | 0.77 | NCF1 (0.55) | KDM4ENCF1HTTMEN1KMT2A | |
| SCHEMBL21864963 | 0.77 | NCF1 (0.55) | NCF1HTTALDH1A1TSHRTTR | |
| SCHEMBL14288335 | 0.76 | NCF1 (0.53) | NCF1ADRA2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL22926818 | 0.75 | KDM4E (0.44) | KDM4ELMNAPOLBCASP6PLAU | |
| SCHEMBL9420844 | 0.74 | NCF1 (0.59) | KDM4ELMNAPOLBNCF1MEN1 | |
| SCHEMBL30301243 | 0.74 | NCF1 (0.59) | KDM4ELMNAPOLBNCF1MEN1 | |
| SCHEMBL116001 | 0.74 | LMNA (1.00) | KDM4ELMNAPOLBCASP6PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286429-B2 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-29 | — | — | US | disclosed |
| US-20230064443-A1 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide Derivatives Useful As a Factor XIa Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-02 | — | — | US | disclosed |
| EP-2956138-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS INC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20180133225-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2018-05-17 | — | — | US | disclosed |
| US-9353122-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140235634-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006022955-A2 | TOPOISOMERASE INHIBITORS | PROPHARMACON, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| EP-1373252-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002076975-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12286429-B2 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors | F11, F12, F13A1 | KDM4E 462/4885LMNA 1288/4885POLB 3803/4885 |
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | KDM4E 987/4885LMNA 1934/4885POLB 15/4885 |
| US-20180133225-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | KDM4E 4786/4885LMNA 2026/4885POLB 3236/4885 |
| US-20230064443-A1 | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide Derivatives Useful As a Factor XIa Inhibitors | F11, F12, F13A1 | KDM4E 544/4885LMNA 923/4885POLB 3544/4885 |
| US-20140235634-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | KDM4E 4786/4885LMNA 2026/4885POLB 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.